More Bad News For The Once Promising Bioresorbable Stent
(Updated) –Problems for the Absorb BVS stent just won’t disappear Bad news for the Absorb BVS stent continues to accumulate, though defenders of the device keep looking for a silver lining. When it was approved in the US last summer the novel device appeared to have a bright future, with many prominent interventional cardiologists predicting...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 31, 2017 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics Abbott ABSORB bioresorbable stent BVS DAPT stent throb Source Type: blogs

Interventional Cardiologists Face Major Obstruction In Treatment Of Total Blockages
–Deep divisions over how CTO patients should be treated. In recent years ambitious interventional cardiologists have started to perform PCI on chronic total occlusions (CTOs), though these lesions have long been recognized as among the most difficult to successfully treat. Many other physicians, including some prominent interventional cardiologists, have expressed grave concerns about this expansion...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 29, 2017 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics chronic total occlusion CTO Source Type: blogs

Controversial Pharma CEO To Chair AHA Charity Ball
–The Wizard of Oz-themed ball seeks to raise $2 million on the yellow brick road. The American Heart Association’s annual Heart & Stroke Ball will be chaired by John Thero, the CEO of Amarin Corporation, the controversial pharmaceutical company. Amarin manufactures the prescription fish oil product Vascepa for which it is aggressively seeking an expanded indication...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 24, 2017 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes AHA Amarin charity conflict of interest Vascepa Source Type: blogs

TV Ads Pushed Inappropriate Use of Testosterone
–Study: prescriptions spiked in direct response to blizzard of ‘Low T’ ads Television ads for testosterone products were highly successful, leading to dramatic increases in the number of men taking testosterone drugs, according to a new study published in the Journal of the American Medical Association. J. Bradley Layton (University of North Carolina, Chapel Hill)...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 21, 2017 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes advertising DTCA low-T testosterone Source Type: blogs

Another HDL Therapy Crashes and Burns
–Failure of pre-beta HDL mimetic puts another nail in the HDL coffin Once again, an HDL-inspired therapy has failed when put to the test in a clinical trial. Although there are still ongoing trials with other HDL-related therapies, most experts now feel that it is time for the field to turn its attention elsewhere and...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 19, 2017 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Prevention, Epidemiology & Outcomes cholesterol HDL triglycerides Source Type: blogs

Ebbinghaus Study May Help Refute Doctor Google
–No neurocognitive adverse effects linked to very low LDL levels Reaching very low LDL levels with a PCSK9 inhibitor was not associated with any increase in neurocognitive adverse events, according to the largest and most rigorous study to assess the topic to date. Small and preliminary studies have raised concerns over the possibility of the...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 18, 2017 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes adverse events evolocumab Fourier neurocognitive PCSK9 Repatha Source Type: blogs

Novel Drug Delivers Long Term Cholesterol Reduction
A novel drug that dramatically lowers LDL cholesterol and needs to be administered only a few times a year has reached a new milestone. Positive results from a phase II study with the drug, now known as inclisiran, were reported at the American College of Cardiology meeting in Washington, DC and published simultaneously in the...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 17, 2017 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Prevention, Epidemiology & Outcomes cholesterol inclisiran LDL Medicines Company PCSK9 Source Type: blogs

FOURIER Shows New Cholesterol Drugs Work, But Are They Worth It?
–Doctors and patients now must wrestle with a modestly effective but expensive drug. As it turns out the PCSK9 inhibitor saga ends not with a bang but a whimper. The results of the highly anticipated FOURIER trial show that the drugs work, though not as powerfully as many had hoped and expected. The question now...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 17, 2017 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes cholesterol evolocumab LDL lipids PCSK9 Repatha Source Type: blogs

Scott Gottlieb ’ s Sham Ideology Rejects Clinical Trials
Donald Trump has nominated Scott Gottlieb to be the next FDA Commissioner. To his credit, Gottlieb is not certifiably crazy like several of the other candidates who were reported to be under consideration for the job. But he is is a deeply conservative ideologue who is determined to reduce the government’s role in healthcare. On two occasions in...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 14, 2017 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics Uncategorized clinical trials FDA hypertension renal denervation Scott Gottlieb Trump Wall Street Journal Source Type: blogs

For Scott Gottlieb, Business Trumps Health
Donald Trump has nominated Scott Gottlieb to be the next FDA Commissioner. To his credit, Gottlieb is not certifiably crazy like several of the other candidates who were reported to be under consideration for the job. But he is is a deeply conservative ideologue who is determined to reduce the government’s role in healthcare. On two occasions in...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 14, 2017 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics American Enterprise Institute CMS FDA Scott Gottlieb TAVR Trump Source Type: blogs

Has Nutrition Science Been Poisoned?
–The inevitable weaknesses of observational and diet studies “Science is the great antidote to the poison of enthusiasm and superstition,” Adam Smith wrote more than 200 years ago. Unfortunately, it often seems as if the science of nutrition has itself been poisoned. Two recently published papers illustrate this problem. Nutrition and Mortality A good example of...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 9, 2017 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes association causality diet nutrition Source Type: blogs

Call For More Calcium Screening Gets Pushback
–But a zero calcium score can be useful to avoid statins, some argue Coronary artery calcium (CAC) scans should be widely used in routine clinical practice to improve the detection of coronary disease in people without known disease, according to the authors of a new review in JACC: Cardiovascular Imaging. But many experts urged caution,...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - March 6, 2017 Category: Cardiology Authors: Larry Husten Tags: Policy & Ethics Prevention, Epidemiology & Outcomes calcium coronary artery calcium CV risk Framingham risk assessment screening Source Type: blogs

Top Cardiologist Blasts Nutrition Guidelines
–Salim Yusuf says new evidence fails to support many major diet recommendations. One of the world’s top cardiologists says that many of the major nutrition guidelines have no good basis in science. “I’m not a nutrition scientist and that may be an advantage because every week in the newspaper we read something is good for...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - February 27, 2017 Category: Cardiology Authors: Larry Husten Tags: Diabetes People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes carbs diet fats guidelines nutrition salt Source Type: blogs

After Yet Another Failure, Stem Cell Leaders Double Down
–Could repeated doses of stem cells turn the tide of negative trials? Despite an unrelieved history of negative trials, stem cell leaders continue to defend their field. In response to the failure of yet another cardiac stem clinical trial, Roberto Bolli, a prominent leader in the field, argued that it’s time for a “paradigm shift” in...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - February 21, 2017 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics searching for the pony Stem cell stem cell therapy Source Type: blogs

International Experts Call Salt Guidelines Far Too Restrictive
A broad group of international experts are recommending a far more modest and less draconian approach to sodium restriction than current U.S. and international guidelines. In a new paper, published online in the European Heart Journal, they also focused on the broad gaps of knowledge in the field and drew attention to the paucity of...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - February 14, 2017 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes evidence guidelines hypertension salt sodium Source Type: blogs

Enormous Rivaroxaban Study Stopped Early For ‘ Overwhelming Efficacy ’
(Updated) –Oral anticoagulant reduced CV events in patients with coronary and peripheral disease. The very large COMPASS study has been stopped early for “overwhelming efficacy,” according to a press release issued by Bayer AG and Janssen, manufacturers of rivaroxaban (Xarelto). The phase 3 trial randomized 27,402 patients with coronary artery disease (CAD) and peripheral artery...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - February 8, 2017 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes Anticoagulant CAD NOAC PAD rivaroxaban Source Type: blogs

New Questions Raised About SPRINT
More questions are being raised about SPRINT, the enormous NIH-funded blood pressure lowering trial. Two recent developments will likely add more obstacles to the already difficult task of applying the results of the trial in the real world. Even before the full results of the trial were first made public the NIH and the SPRINT...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - February 8, 2017 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes blood pressure data sharing hypertension open data SPRINT Source Type: blogs

27,000 Patient PCSK9 Inhibitor Trial Meets Main Endpoints
–Cardiovascular outcomes finally available for PCSK9 inhibitors. Amgen announced on Thursday afternoon that the FOURIER trial had met both its primary composite endpoint (cardiovascular death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina or coronary revascularization) and the even more rigorous key secondary composite endpoint (cardiovascular death, non-fatal MI or non-fatal stroke). The company also...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - February 2, 2017 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes Amgen cholesterol CVOT evolocumab PCSK9 statins Source Type: blogs

In Which I Go Under The Knife And Learn About Medicine In The Real World
I’m not a doctor but I thought I knew something about anticoagulation. Over the course of a career covering cardiology I’ve written countless stories about heparin, warfarin, the low molecular weight heparins, and the new oral anticoagulants. So when I had bilateral total knee replacement a few weeks ago I thought I knew what to...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - January 27, 2017 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics anticoagulation aspirin Evidence-based medicine Lovenox total knee replacement Xarelto Source Type: blogs

Long Unsuccessful Heart Failure Drug Once Again At Center Of Controversy
–The long, strange 30-year journey of BiDil. It’s been buried in the avalanche of related news but there’s an interesting and somewhat bizarre cardiology angle to the debate over Trump’s nomination of Tom Price to be the next HHS Secretary. ProPublica reported on Friday that last summer Price went to bat for the makers of...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - January 23, 2017 Category: Cardiology Authors: Larry Husten Tags: Heart Failure People, Places & Events Policy & Ethics Uncategorized ACE inhibitors BiDil conflict of interest HHS Tom Price Source Type: blogs

Screen-And-Treat to Prevent Diabetes Doomed to Fail
Screening must be supplemented by broader public health approaches. Screen and treat strategies to prevent type 2 diabetes are doomed to failure, according to a large new systematic review and meta-analysis published in The BMJ.  Instead, the authors said and outside experts agreed, any effort to combat the already enormous and still growing problem of type 2...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - January 4, 2017 Category: Cardiology Authors: Larry Husten Tags: Diabetes Policy & Ethics Prevention, Epidemiology & Outcomes glucose metformin population measures Public health screening Source Type: blogs

2016: Great Year Or Greatest Year Ever?
Editor’s note: Once again Larry was too depressed to write the 2016 yearly review. (Actually, he’s hiding under his bed.) Veteran healthcare journalist and eternal optimist Candide Corn has again kindly agreed to take over the task this year. Candide’s motto is “all is for the best in the best of all possible worlds.” What a great year!...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - December 21, 2016 Category: Cardiology Authors: Larry Husten Tags: Classics Interventional Cardiology & Surgery People, Places & Events Policy & Ethics year in review Source Type: blogs

More Shots Fired in ‘ Sugar War ’
–Industry-sponsored study questions current guidelines on dietary sugar. Dietary guidelines relating to sugar— all of which recommend significant reductions in sugar intake— are based on weak evidence and are not trustworthy, according to a systematic review published in Annals of Internal Medicine. But an accompanying editorial points out that the systematic review is itself not...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - December 19, 2016 Category: Cardiology Authors: Larry Husten Tags: Diabetes People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes Coca Cola dietary guidelines nutrition sugar Source Type: blogs

Novartis Withdraws Support For Controversial Entresto Contest
(Updated) Novartis will no longer sponsor a contest designed to support the publication of peer review articles about Entresto, the company’s important new heart failure drug. The contest is taking place on Cureus, an open access journal, publishing platform, and vehicle for industry-sponsored content. The contest offered $10,000 in rewards for articles supporting a recent...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - December 19, 2016 Category: Cardiology Authors: Larry Husten Tags: Heart Failure People, Places & Events Policy & Ethics contest Entresto Guideline LCZ Novartis Source Type: blogs

Novartis Contest Rewards Positive Peer Review Articles About Entresto
(Updated) Despite the fact that it had one of the biggest clinical trial successes in recent years, the Novartis heart failure drug Entresto has been struggling to gain acceptance in the marketplace. To help improve its position Novartis has turned to an old marketing trick, though this trick– a company-sponsored competition– has rarely been used by the...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - December 15, 2016 Category: Cardiology Authors: Larry Husten Tags: Classics Heart Failure People, Places & Events Policy & Ethics competition Cureus Entresto Guideline LCZ publishing Source Type: blogs

Seeking Profit and Investors, Rogue Lab Moves Into Small Hospitals
A controversial new laboratory company specializing in “advanced cardiovascular risk testing” is developing an innovative, highly profitable– and legally dubious– new business model. Details of the scheme are spelled out in a “Management Presentation” slide presentation sent to me by a confidential source. The slide presentation, according to my source, is  being shown by executives at True Health...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - December 9, 2016 Category: Cardiology Authors: Larry Husten Tags: Classics People, Places & Events Policy & Ethics HDL Lab Health Diagnostic Laboratory lab tests True Health Diagnostics zombie lab Source Type: blogs

The GiveAway Act
The 21st Century Cures Act should be called the 21st Century GiveAway Act. The Act may not even deliver on its main attraction– the funding of new research– but will instantly definitely give a regulatory boost to a host of special interests, including drug and device makers. As Michael Hiltzik writes in the LA Times,...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - December 6, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics 21st Century Cures Act FDA regulation summary data Source Type: blogs

Telling People What They Want To Hear: Alt-Med And Donald Trump
Donald Trump won* the election because he told people what they wanted to hear. Alternative medicine is growing in popularity because it tells people what they want to hear. Of course, there’s a big difference between telling people what they want to hear and actually delivering on those promises. He can say it as often as he...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - December 4, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics alternative medicine Trump Source Type: blogs

Genetic Studies Offer Hint Of Clinical Benefits-And Risks- of PCSK9 Inhibitors
–Both cardiovascular benefits and increase in diabetes seem likely. There is no more eagerly awaited question in cardiovascular medicine than the clinical role of the PCSK9 inhibitors. The first reports from a series of outcomes trials are not due until next year. But two large genetic studies published this week deliver strong indirect evidence that...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - November 30, 2016 Category: Cardiology Authors: Larry Husten Tags: Diabetes Policy & Ethics Prevention, Epidemiology & Outcomes cholesterol genetic variants LDL Mendelian randomization PCSK9 statins Source Type: blogs

Prenatal Genetic Test Billing Practices Questioned
–Sequenom billed insurance companies $2,760 but let patients pay only $200? Patients who order an expensive prenatal genetic test from Sequenom are being told that they will not be held responsible for the vast majority of the bill if it is denied by insurance. This policy may appear to benefit patients but may be considered a...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - November 29, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics false claims genetic test prenatal testing Sequenom Source Type: blogs

Saturated Fats Linked To Heart Disease Once Again
–But critics say that observational studies can’t establish causal relationship. A prominent group of nutrition researchers have once again linked saturated fats to increased coronary heart disease. The new paper, published in BMJ, is the third paper in the past year to decry saturated fats. Along with the previous two papers, published in JACC and JAMA Internal...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - November 27, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes cholesterol diet dietary guidelines nutrition saturated fats Source Type: blogs

Guest Post: Two Nations Separated by 5.3 mm
Editor’s note: This guest post is by Saurabh Jha, MBBS, a radiologist at the University of Pennsylvania. This post will also be published on The Health Care Blog, where Jha is the associate editor. A popular meme is that the US spends more on healthcare than other developed nations but has nothing to show for...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - November 23, 2016 Category: Cardiology Authors: Larry Husten Tags: Policy & Ethics Prevention, Epidemiology & Outcomes AAA Saurabh Jha screening Source Type: blogs

How The Internet Brought Us Donald Trump
Does the internet expand our world? Does it lead us to a broader and richer view of our world and ourselves? It seemed like a simple question. The year was 1994 and the internet was still new. I was sitting in a classroom full of MIT students as a guest during my year as a...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - November 20, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Uncategorized election internet Trump Source Type: blogs

How The Internet Brought Us To Donald Trump
Does the internet expand our world? Does it lead us to a broader and richer view of our world and ourselves? It seemed like a simple question. The year was 1994 and the internet was still new. I was sitting in a classroom full of MIT students as a guest during my year as a...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - November 20, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Uncategorized election internet Trump Source Type: blogs

Mixed Results For ApoA-1 Therapies
–It’s still not time to write the obituary for all HDL therapies. There was good news and bad news for a category of experimental drugs that attempt to mimic the putative beneficial effect of HDL at the American Heart Association meeting in New Orleans. Thirteen years after setting the field on fire with a promising...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - November 16, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes ACS Apo!-1 cholesterol CSL HDL Milano Source Type: blogs

Lunchroom Scandal At The AHA: Day Two Of Buttergate
–After a CardioBrief investigation the American Heart Association changes the lunchroom menu There is no better proof that journalism can change the world– both for the good and the bad– than Buttergate. Yesterday your intrepid reporter exposed the ongoing scandal of Buttergate taking place within the press lunchroom at the American Heart Association meeting in New...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - November 15, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes AHA american heart association dietary guidelines Fat nutrition sugar Source Type: blogs

More Progress For Novel PCSK9 Drug
–The PCSK9 synthesis inhibitor from The Medicines Company is getting close to phase 3 trials. More early information continues to accumulate about a novel cholesterol drug under development by The Medicines Company. The drug, which was initially created by Alnylam Pharmaceuticals, uses RNA interference technology to inhibit the synthesis of PCSK9 in the liver. The main...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - November 15, 2016 Category: Cardiology Authors: Larry Husten Tags: Prevention, Epidemiology & Outcomes Alnylam inclisiran PCSK9 PCSK9si The Medicines Company Source Type: blogs

Is The American Heart Association Trying To Kill Health Reporters?
The answer is no. The AHA is not trying to kill us. But its dietary advice is consistently confusing and occasionally wrong, and health reporters in New Orleans may end up as collateral damage. Just take a look at what’s being served in the press room at the big American Heart Association meeting going on now...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - November 14, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes Uncategorized AHA American Heart Assocition Fat low-carb nutrition nutrition guideline sugar Source Type: blogs

Statin Nation ‘ Census ’ Highlights Major Disparities
–Women, minorities treated at significantly lower rates Anyone reading this is almost certainly aware of the enormous importance of statins in the current health scene. But until now they may have had a hard time to bring precise numbers and statistics to this all important story. Now data from a large federal survey confirm that...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - November 14, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes primary prevention statins Source Type: blogs

No Cognitive Benefit from Heart Drugs in HOPE-3
–Substudy finds mental function unimproved by BP, cholesterol treatments NEW ORLEANS — A large substudy of the HOPE-3 trial found no benefit relating to cognitive function in patients who took cholesterol or blood pressure-lowering drugs. In recent years cognitive decline and dementia have emerged as a concern equal if not even greater than cardiovascular disease...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - November 13, 2016 Category: Cardiology Authors: Larry Husten Tags: Policy & Ethics Prevention, Epidemiology & Outcomes antihypertensive drugs Cognition dementia primary prevention statins Source Type: blogs

Long-Term Benefit in HF Patients Elusive for Novel Vasodilator
–Investigational drug ularitide had no effect on mortality or clinical outcomes NEW ORLEANS — Short term vasodilator treatment for acute heart failure in the hospital did not lead to long term clinical benefits in the largest and most rigorous trial in the field yet performed, researchers said. In the TRUE-AHF trial 2,157 patients with acute...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - November 13, 2016 Category: Cardiology Authors: Larry Husten Tags: Heart Failure acute heart failure ADHF Cardiorentis ularitide vasodilator Source Type: blogs

Debate Ensues As USPSTF Finalizes Statin Primary Prevention Guideline
–Broad disagreement about how, when, and if to use statins. The U.S. Preventive Services Task Force (USPSTF) has issued final recommendations regarding the use of statins for primary prevention of cardiovascular disease in adults. The recommendations, first proposed last December, are broadly consistent with the 2013 American College of Cardiology/American Heart Association guidelines. But accompanying the...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - November 13, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes cardiovascular risk guidelines primary prevention statins USPSTF Source Type: blogs

Novel Cholesterol Therapy Flops And Company Ends Development
–13 years after ApoA-1 Milano sparked excitement the novel HDL therapy appears to be dead. After 13 years and despite the efforts of 3 separate companies, the novel cholesterol therapy known as ApoA-1 Milano appears to be dead. On Monday afternoon the Medicines Company announced that it had discontinued development of the drug and would...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - November 8, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Prevention, Epidemiology & Outcomes apo-A-1 Esperion HDL Medicines Company Pfizer Source Type: blogs

Cardiac Devices Could Become a Big Problem For Califf And The FDA
–Approvals with no strong evidence of efficacy: What could go wrong?  The FDA has a big problem. It likes to approve new drugs and devices. Approvals look good politically and allow the FDA to boast each year about their large number of approvals. But when the FDA approves a drug or device that doesn’t work...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - November 7, 2016 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics Califf devices FDA FDA approval Source Type: blogs

Early Watchman Experience Reassuring, But Many Questions Remain
In the year and a half after its approval the Watchman left atrial appendage closure device was successfully implanted 95.6% of the time, or more than 3,600 times out of a total of 3,822 consecutive cases. The finding comes from procedural data collected by Boston Scientific and presented at TCT by Vivek Reddy (Mt. Sinai)...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - November 4, 2016 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics Boston Scientific Left atrial appendage Watchman Source Type: blogs

The Impact Of ABSORB II: Down The Slippery Slope
When it was approved earlier this year in July the Absorb (Abbott) bioresorbable stent provoked a fair amount of discussion about the “slippery slope of noninferiority.” Although the stent met the FDA criteria for approval, the available trial results went in the wrong direction and there was a particularly concerning warning sign of a higher...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - November 2, 2016 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics Abbott ABSORB bioresorbable stent FDA noninferiority postapproval stents Source Type: blogs

Pfizer Ends Development Of Its PCSK9 Inhibitor
–Immune issues and diminishing efficacy doomed the new drug. Pfizer announced on Tuesday that it was discontinuing development of bococizumab, its cholesterol-lowering PCSK9 inhibitor under development. “The totality of clinical information now available for bococizumab, taken together with the evolving treatment and market landscape for lipid-lowering agents, indicates that bococizumab is not likely to provide...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - November 1, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes bococizumab cholesterol CVOT PCSK9 Pfizer Source Type: blogs

Debaters At Interventional Cardiology Meeting Literally Put The Gloves On
The world’s premiere interventional cardiology meeting now features cardiologists wearing boxing shorts and gloves. The Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, DC kicked off  with a “Saturday Night Fights” theme for its debate session, and the participants– nearly all greying, eminent male interventional cardiologists– adopted the theme whole-heartedly. All lovey-dovey at the start of #TCT2016 fights pic.twitter.com/upGprIcxkQ...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - October 30, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Cardiology Saturday Night Fights sexism TCT women in cardiology Source Type: blogs

Impella No Better Than IABP in Cardiogenic Shock
–Underpowered IMPRESS trial shows no mortality benefit A rare randomized trial and a new meta-analysis both failed to find any evidence that Impella mechanical circulatory support devices are any better than intra-aortic balloon pumps (IABPs) for patients with cardiogenic shock. For many years, the intra-aortic balloon pump has been the standard device to increase circulation...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - October 30, 2016 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery MI/ACS People, Places & Events Policy & Ethics Abiomed cardiogenic shock IABP Impella mechanical circulatory support Source Type: blogs

Universal Child FH Screening Proposed
–Novel strategy would identify both children and adults at high risk for CV events. Doctors in the U.K. are proposing a novel strategy to identify very young children with familial hypercholesterolemia (FH). The strategy would also identify and help prevent events in the parents who also have FH. The new approach begins with a heel-stick...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - October 26, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes cholesterol familial hypercholesterolemia FH LDL screening Source Type: blogs